| Clinical Observation of Patients with Hematologic Malignancies Treated with Hematopoietic Stem Cell Transplantation |
| |
| 作者姓名： | 张东华 张路 肖毅 黄伟 李登举 冉丹 黄亮 周剑锋 黄梅 孙汉英 刘文励 |
| |
| 作者单位： | Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology，Department of Hematology，Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China，Wuhan 430030，China |
| |
| 摘 要： | HSCTincludingauto HSCT ,myeloablativeallo HSCTandnonmyeloablativeallo HSCTwhichdevel opedrecently ,isthebesttherapeusisforhematologicmalignanciesnowadays .FromApril 1996toApril2 0 0 4 30patientswithhematologicmalignanciesun derwentHSCTinourhospital ,asrep…
|
| 关 键 词： | 临床报告 血液学 恶性作用 造血干细胞 细胞移植 HSCT |
| 收稿时间： | 29 December 2003 |
Clinical observation of patients with hematologic malignancies treated with hematopoietic stem cell transplantation |
| |
| Zhang Donghua,Zhang Lu,Xiao Yi,Huang Wei,Li Dengju,Ran Dan,Huang Liang,Zhou Jianfeng,Huang Mei,Sun Hanying,Liu Wenli.Clinical Observation of Patients with Hematologic Malignancies Treated with Hematopoietic Stem Cell Transplantation[J].Journal of Zuazhong University of Science and Technology: Medical Edition,2004,24(4):345-349. |
| |
| Authors: | Zhang Donghua Zhang Lu Xiao Yi Huang Wei Li Dengju Ran Dan Huang Liang Zhou Jianfeng Huang Mei Sun Hanying Liu Wenli |
| |
| Institution: | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China |
| |
| Abstract: | Summary To evaluate the therapeutic effect of hematopoietic stem cell transplantation (HSCT), we performed HSCT in 30 patients with
hematologic maligancies. Of the 30 patients, 10 underwent autologous peripheral blood stem cell transplantation (auto-PBSCT),
13 underwent myeloablative allogeneic HSCT while 7 underwent nonmyeloablative allogeneic HSCT, which were designated as autologous
group, myeloablative group and nonmyeloablative group, respectively. All patients except the one who underwent cord blood
transplantation, were successfully engrafted. Median time for the granulocytes≥0.5×105/L and platelets≥20×109/L were 12 days and 13 days respectively in autologous group, 16 days and 19 days in myeloablative group, 15 days and 12 days
in nonmyeloablative group. In myeloablative group, acute graft-versus-host discases (aGVHD) was observed in 3 patients, all
of which were I–II grade. Oral mucous cGVHD was observed in 1 patient. In nonmyeloablative group, 1 patient developed intestinal
aGVHD grade IV and cutaneous cGVHD was induced by donor lymphocyte infusions (DLI) in 3 patients, 1 patient had hematological
relapse in autologous group, 1 patient had cytogenetic relapse in myeloablative group. In nonmyeloablative group 3 patients
had cytogenetic relapse and were cured by DLI, 1 patient had hematological relapse, 4 of the 30 patients died of infection
(2 patients), grade IV aGVHD (1) and relapse (1) respectively, 26 patients are still alive. 3 years overall survival (OS)
and 3 years disease free survival (DFS) were 100% and 64.81% respectively in autologous group, 78.75% and 63% respectively
in myeloablative group while both 66. 67% in nonmycloablative group. In conclusion, autologous group had less transplant-related
complications and mortality. Active prophylaxis of relapse could significantly promote DFS. The transplant-related mortality
limited DFS in myeloablative group. More relapses occurred in nonmyeloablative group, but could be cured by DLI.
ZHANG Donghua, male, born in 1962, Associate Professor |
| |
| Keywords: | hematopoietic stem cell transplantation leukemia lymphoma disease free survival |
| 本文献已被 CNKI 万方数据 SpringerLink 等数据库收录！ |
|
